Table 1

Participant characteristics

Mean ± SD
n = 41
Range
(min–max)
Age (years)58 ± 1132–74
Gender (% women)69%
Ethnicity (% Caucasian)85%
Height (cm)166.1 ± 9.2151.0–195.0
Weight (kg)77.1 ± 17.151.0–121.7
RA characteristics
Disease activity (DAS28)3.18 ± 1.750.00–6.28
Erythrocyte sedimentation rate (mmHrs)16.5 ± 15.82.0–69.0
Functional disability (HAQ)1.67 ± 0.561.00–3.00
Disease duration (years)7.2 ± 8.71–37
Morning stiffness (min/day)35 ± 410–180
Current treatment
Anti-TNF (% yes)10%
DMARDS (% yes)56%
NSAIDS (% yes)29%
Analgesics (% yes)24%
CVD risk factors
Total cholesterol (mmol/L)5.0 ± 0.93.3–6.9
HDL cholesterol (mmol/L)1.4 ± 0.40.8–2.5
Systolic blood pressure (mm Hg)136 ± 1799–181
Diastolic blood pressire (mm Hg)81 ± 867–99
BMI (kg/m2)27.8±5.519.7–42.0
Smoker (% current smokers)7%
Diabetes (% yes)7%
QRISK (%)15.8 ± 11.90.2–48.0
Activity behaviour
Sedentary time (min/day)514.0 ± 65.6350–672
Light-intensity PA (min/day)257.9 ± 67.8121–423
Moderate-to-vigorous PA (min/day)18.0 ± 17.20.0–76
Sedentary bout length (≥20 min) (min/bout)31.1 ± 2.327–38
Valid wear time (min/day)789.9 ± 41.8698–1467
  • The HAQ typically uses a response scale from 0 (without any difficulty) to 3 (unable to do). In the PARA study, the HAQ was scored on response scale starting at 1 (without any difficulty) to 4 (unable to do).

  • One participant who did not provide valid daily accelerometer data at baseline (excluded as an outlier) was included in the current secondary analysis, as their hourly data was considered valid. However, this participant was excluded for the purpose producing descriptive statistics to indicate daily estimates of behaviour.

  • Anti-TNF, anti Tumor Necrosis Factor; BMI, body mass index; CVD, cardiovascular disease risk; DAS28, Disease Activity Score-28; DMARDS, Disease-Modifying Anti-Rheumatic Drugs; HAQ, Health Assessment Questionnaire; HDL, high-density lipoprotein; NSAIDS, non-steroidal anti-inflammatory drugs; PA, physical activity.